Receiving four or fewer cycles of therapy predicts poor survival in newly diagnosed transplant-ineligible patients with myeloma who are treated with bortezomib-based induction

Stephen Boyle; Cameron Wellard; Elizabeth M. Moore; Hilary Blacklock; Simon J. Harrison; Phoebe Joy Ho; Jay Hocking; Zoe K. McQuilten; Hang Quach; Ruth Spearing; Erica M. Wood; Andrew Spencer; Peter Mollee; Myeloma and Related Diseases Registry investigators

doi:10.1111/ejh.13677

Receiving four or fewer cycles of therapy predicts poor survival in newly diagnosed transplant-ineligible patients with myeloma who are treated with bortezomib-based induction

Stephen Boyle, Cameron Wellard, Elizabeth M. Moore, Hilary Blacklock, Simon J. Harrison, Phoebe Joy Ho, Jay Hocking, Zoe K. McQuilten, Hang Quach, Ruth Spearing, Erica M. Wood, Andrew Spencer, Peter Mollee, Myeloma and Related Diseases Registry investigators

Research output: Contribution to journal › Letter › Other › peer-review

2 Citations (Scopus)

Original language	English
Pages (from-to)	497-499
Number of pages	3
Journal	European Journal of Haematology
Volume	107
Issue number	4
DOIs	https://doi.org/10.1111/ejh.13677
Publication status	Published - Oct 2021

Access to Document

10.1111/ejh.13677

345165044-oaAccepted author manuscript, 278 KB

Cite this

Boyle, S., Wellard, C., Moore, E. M., Blacklock, H., Harrison, S. J., Ho, P. J., Hocking, J., McQuilten, Z. K., Quach, H., Spearing, R., Wood, E. M., Spencer, A., Mollee, P., & Myeloma and Related Diseases Registry investigators (2021). Receiving four or fewer cycles of therapy predicts poor survival in newly diagnosed transplant-ineligible patients with myeloma who are treated with bortezomib-based induction. European Journal of Haematology, 107(4), 497-499. https://doi.org/10.1111/ejh.13677

@article{76b4c7a4f7d64a37bd146ba721a23f24,

title = "Receiving four or fewer cycles of therapy predicts poor survival in newly diagnosed transplant-ineligible patients with myeloma who are treated with bortezomib-based induction",

author = "Stephen Boyle and Cameron Wellard and Moore, \{Elizabeth M.\} and Hilary Blacklock and Harrison, \{Simon J.\} and Ho, \{Phoebe Joy\} and Jay Hocking and McQuilten, \{Zoe K.\} and Hang Quach and Ruth Spearing and Wood, \{Erica M.\} and Andrew Spencer and Peter Mollee and \{Myeloma and Related Diseases Registry investigators\}",

year = "2021",

month = oct,

doi = "10.1111/ejh.13677",

language = "English",

volume = "107",

pages = "497--499",

journal = "European Journal of Haematology",

issn = "0902-4441",

publisher = "Wiley-Blackwell",

number = "4",

}

Boyle, S, Wellard, C, Moore, EM, Blacklock, H, Harrison, SJ, Ho, PJ, Hocking, J, McQuilten, ZK, Quach, H, Spearing, R, Wood, EM , Spencer, A, Mollee, P & Myeloma and Related Diseases Registry investigators 2021, 'Receiving four or fewer cycles of therapy predicts poor survival in newly diagnosed transplant-ineligible patients with myeloma who are treated with bortezomib-based induction', European Journal of Haematology, vol. 107, no. 4, pp. 497-499. https://doi.org/10.1111/ejh.13677

Receiving four or fewer cycles of therapy predicts poor survival in newly diagnosed transplant-ineligible patients with myeloma who are treated with bortezomib-based induction. / Boyle, Stephen; Wellard, Cameron; Moore, Elizabeth M. et al.
In: European Journal of Haematology, Vol. 107, No. 4, 10.2021, p. 497-499.

Research output: Contribution to journal › Letter › Other › peer-review

TY - JOUR

T1 - Receiving four or fewer cycles of therapy predicts poor survival in newly diagnosed transplant-ineligible patients with myeloma who are treated with bortezomib-based induction

AU - Boyle, Stephen

AU - Wellard, Cameron

AU - Moore, Elizabeth M.

AU - Blacklock, Hilary

AU - Harrison, Simon J.

AU - Ho, Phoebe Joy

AU - Hocking, Jay

AU - McQuilten, Zoe K.

AU - Quach, Hang

AU - Spearing, Ruth

AU - Wood, Erica M.

AU - Spencer, Andrew

AU - Mollee, Peter

AU - Myeloma and Related Diseases Registry investigators

PY - 2021/10

Y1 - 2021/10

UR - https://www.scopus.com/pages/publications/85109024631

U2 - 10.1111/ejh.13677

DO - 10.1111/ejh.13677

M3 - Letter

C2 - 34129711

AN - SCOPUS:85109024631

SN - 0902-4441

VL - 107

SP - 497

EP - 499

JO - European Journal of Haematology

JF - European Journal of Haematology

IS - 4

ER -

Receiving four or fewer cycles of therapy predicts poor survival in newly diagnosed transplant-ineligible patients with myeloma who are treated with bortezomib-based induction

Access to Document

Other files and links

Cite this